Semax 10mg

Alpha Elite Semax 10 mg — Lyophilized Research Peptide

Alpha Elite Semax 10 mg is a seven-amino-acid research peptide supplied as a lyophilized, freeze-dried powder in a sealed glass vial. It is intended for controlled laboratory research, analytical testing, peptide characterization, degradation studies, gene-expression analysis, and scientific investigation.

Semax is associated with the amino-acid sequence Met-Glu-His-Phe-Pro-Gly-Pro, commonly abbreviated as MEHFPGP. The peptide combines the ACTH(4–7) sequence Met-Glu-His-Phe with the C-terminal tripeptide Pro-Gly-Pro and is commonly described in scientific literature as an ACTH(4–10) analog.

Published biochemical, cellular, transcriptomic, proteomic, and preclinical studies have examined Semax in relation to peptide biodegradation, peptide-fragment formation, plasma-membrane interactions, neurotrophin-associated gene expression, transcriptomic profiles, immune- and vascular-system-related genes, neurotransmission-associated pathways, protein-expression measurements, and metal-ion coordination.

The identity, labeled quantity, purity, amino-acid sequence, molecular form, counterion content, residual solvents, degradation products, and analytical specifications of Alpha Elite Semax 10 mg should be confirmed using the applicable batch-specific certificate of analysis.

Semax Sequence and Molecular Identity

Semax is associated with the following seven-residue sequence:

Met-Glu-His-Phe-Pro-Gly-Pro

The one-letter sequence abbreviation is:

MEHFPGP

The sequence contains:

• Methionine
• Glutamic acid
• Histidine
• Phenylalanine
• Proline
• Glycine
• Proline

The N-terminal four-residue sequence, Met-Glu-His-Phe, corresponds to ACTH(4–7). The C-terminal Pro-Gly-Pro sequence is commonly abbreviated as PGP. Together, these regions form the complete seven-amino-acid Semax sequence.

Relevant molecular research areas include:

• Semax sequence confirmation
• MEHFPGP peptide analysis
• Seven-amino-acid peptide characterization
• ACTH(4–7)-PGP research
• ACTH(4–10) analog research
• Pro-Gly-Pro-containing peptide research
• Glyproline peptide research
• Molecular-mass confirmation
• Amino-acid composition analysis
• Peptide-fragmentation analysis
• Chromatographic purity analysis
• Comparative peptide-sequence research

The product name alone does not establish the sequence, purity, quantity, molecular form, or analytical equivalence of a specific commercial vial. Those characteristics should be established through validated product-specific testing.

ACTH-Fragment and Pro-Gly-Pro Research

Semax contains two structural regions frequently examined in comparative peptide research:

• The N-terminal ACTH(4–7) fragment: Met-Glu-His-Phe
• The C-terminal Pro-Gly-Pro tripeptide: Pro-Gly-Pro

Researchers have compared the complete Semax sequence with ACTH-related fragments, PGP, Semax metabolites, and other related peptides to examine how individual sequence regions contribute to degradation patterns, transcriptomic measurements, and cellular responses.

Research involving these regions may include:

• Parent-peptide and fragment comparisons
• ACTH-fragment characterization
• PGP tripeptide research
• Sequence-dependent biodegradation
• Structure–activity relationships
• Transcriptomic comparisons
• Peptide-metabolite analysis
• N-terminal and C-terminal cleavage
• Comparative cellular signaling
• Glyproline-associated peptide research

Findings involving PGP or another isolated fragment should not automatically be treated as findings involving the complete MEHFPGP sequence. Likewise, observations involving complete Semax should not automatically be attributed to each individual fragment.

Semax Biodegradation and Peptide-Fragment Research

A study using uniformly labeled Semax examined its degradation in the presence of plasma membranes and cultured neuronal and glial cells obtained from rat basal forebrain tissue. High-performance liquid chromatography was used to separate and analyze peptide fragments formed during incubation.

The investigators reported that predominant degradation processes included removal of the N-terminal Met-Glu sequence, removal of the C-terminal Gly-Pro sequence, and formation of shorter pentapeptide products. Differences were observed between degradation patterns produced in neuronal and glial cell systems.

Relevant degradation research includes:

• Parent-peptide stability
• Proteolytic peptide degradation
• Plasma-membrane-associated degradation
• Neuronal-cell degradation models
• Glial-cell degradation models
• N-terminal peptide cleavage
• C-terminal peptide cleavage
• Pentapeptide-fragment formation
• MEHFPGP degradation pathways
• Met-Glu fragment removal
• Gly-Pro fragment removal
• Time-dependent degradation
• HPLC fragment separation
• Comparative cellular degradation
• Peptidase-associated research

A separate tritium-labeling study identified His-Phe-Pro-Gly-Pro and Pro-Gly-Pro as major Semax biodegradation products under the experimental conditions evaluated.

The identity and abundance of degradation products may vary according to biological matrix, enzyme activity, incubation time, temperature, peptide concentration, sample preparation, and analytical method.

Results produced with experimental radiolabeled material or isolated cellular systems do not independently establish the degradation characteristics of Alpha Elite Semax 10 mg.

Plasma-Membrane Binding Research

Semax binding and biodegradation have also been examined using plasma membranes isolated from rat forebrain basal nuclei.

A radiolabeled-peptide study reported time-dependent, reversible, and specific binding under the experimental conditions used. The same investigation employed HPLC analysis to examine Semax degradation during incubation with the membrane preparation.

Research areas may include:

• Plasma-membrane peptide binding
• Reversible binding measurements
• Time-dependent ligand association
• Calcium-dependent binding
• Ligand-binding affinity
• Binding-site concentration
• Membrane-associated peptide degradation
• Radiolabeled peptide analysis
• HPLC degradation analysis
• Comparative membrane systems

These experimental binding measurements were generated using rat membrane preparations. They do not identify a confirmed human receptor or establish equivalent binding behavior in other tissues, species, or products.

Neurotrophin Gene-Expression Research in Cell Culture

Semax has been examined in cultured glial cells obtained from newborn rat basal forebrain tissue.

A 2001 study measured messenger-RNA levels for brain-derived neurotrophic factor, commonly abbreviated as BDNF, and nerve growth factor, commonly abbreviated as NGF. Researchers reported time-dependent changes in both transcripts following experimental Semax exposure, with the largest measured increases occurring at the 30-minute study point.

Relevant cell-culture research includes:

• Rat glial-cell culture
• BDNF messenger-RNA expression
• NGF messenger-RNA expression
• Neurotrophin gene regulation
• Time-dependent transcriptional responses
• Basal-forebrain cell research
• Real-time gene-expression analysis
• Cellular peptide-response research
• Comparative transcript measurements
• Neurotrophin-associated pathways

These results were obtained from cultured rat glial cells using specific concentrations and laboratory conditions. They do not establish neurological, cognitive, behavioral, or therapeutic effects in humans.

Neurotrophin Gene Expression in Rat Brain

A subsequent in-vivo study examined Bdnf and Ngf expression in several regions of the rat brain after experimental Semax exposure.

Real-time PCR analysis identified region-specific differences in neurotrophin messenger-RNA measurements. Changes were reported in the hippocampus, brainstem, cerebellum, and frontal cortex, and the direction of change differed by gene and brain region.

Research areas included:

• Hippocampal gene expression
• Frontal-cortex gene expression
• Brainstem gene expression
• Cerebellar gene expression
• Bdnf transcription
• Ngf transcription
• Region-specific gene regulation
• Real-time PCR analysis
• Time-dependent neurotrophin expression
• Comparative brain-region analysis

Additional studies examined the temporary dynamics of Bdnf and Ngf expression at multiple experimental time points, further demonstrating that the measured transcriptional response may change according to both brain region and sampling time.

These observations were produced in animal models. They do not establish cognitive enhancement, memory improvement, neuroprotection, or other personal-use outcomes.

Transcriptomic Research Under Baseline Conditions

A 2024 study used high-throughput RNA sequencing to examine gene-expression changes in the frontal cortex of rats exposed to Semax under otherwise normal experimental conditions.

Researchers identified differentially expressed genes and compared the Semax transcriptomic profile with that produced by another ACTH-derived peptide. The identified genes were associated with several metabolic, immune, neural-signaling, and ion-channel-related pathways.

Relevant research areas include:

• High-throughput RNA sequencing
• Frontal-cortex transcriptomics
• Differentially expressed genes
• Gene-network analysis
• Immune-system-associated transcripts
• Neural-signaling-associated transcripts
• Ion-channel regulation
• Metabolic-pathway analysis
• Comparative ACTH-peptide research
• Bioinformatic pathway analysis
• Baseline gene-expression profiling
• Structure-dependent transcriptomic differences

The study also demonstrated that transcriptomic findings under baseline conditions may differ from those observed in experimentally altered or damaged tissue.

These results apply to the specific rat model, peptide preparations, experimental schedule, sampling time, RNA-sequencing method, and statistical thresholds used by the investigators.

Transcriptomic Research in Focal Ischemia Models

Genome-wide transcriptional studies have examined Semax in rat models involving experimentally induced focal cerebral ischemia.

A 2014 study analyzed cerebral-cortex tissue at multiple time points after permanent middle cerebral artery occlusion. Researchers reported Semax-associated changes in genes connected with immune-system activity, chemokine signaling, immunoglobulin expression, vascular development, endothelial-cell processes, and smooth-muscle-cell migration.

A later transcriptomic analysis compared Semax and PGP in the same general class of animal models and identified changes involving immune-response, interferon-associated, cytokine, stress-response, ribosomal-protein, and neurotransmission-related genes.

Research areas include:

• Genome-wide expression analysis
• Focal cerebral-ischemia models
• Cerebral-cortex transcriptomics
• Immune-response gene expression
• Chemokine-associated genes
• Immunoglobulin-associated genes
• Interferon-signaling pathways
• Cytokine-associated transcripts
• Stress-response genes
• Ribosomal-protein genes
• Vascular-system-associated genes
• Endothelial-cell-associated pathways
• Neurotransmission-associated genes
• Semax and PGP comparisons

These studies were performed in rat models involving experimentally induced brain injury. Transcriptomic changes do not independently establish neurological benefits, tissue recovery, clinical effectiveness, or appropriate human use.

Ischemia-Reperfusion RNA-Sequencing Research

A 2020 study used RNA sequencing to examine the brain transcriptome in rats after transient middle cerebral artery occlusion and experimental Semax exposure.

Researchers identified hundreds of differentially expressed genes and used bioinformatic analysis to classify changes involving inflammatory processes, neurotransmission, and other signaling pathways under the specific experimental conditions evaluated.

Research areas included:

• Transient middle cerebral artery occlusion
• Ischemia-reperfusion models
• RNA-sequencing analysis
• Differential gene expression
• Neurotransmission-associated pathways
• Inflammation-associated pathways
• Gene-ontology analysis
• Biological-network analysis
• Cortex transcriptomics
• Comparative treatment-group profiling

The findings were generated from an animal injury model and do not establish treatment, protective, restorative, or clinical outcomes in humans.

Protein-Expression Research

Protein-level research has evaluated selected molecular measurements after experimental Semax exposure in a rat ischemia-reperfusion model.

A 2021 investigation examined proteins associated with inflammation, stress signaling, cell-death pathways, transcriptional regulation, and cellular response. Measurements included MMP-9, c-Fos, JNK, and CREB-associated protein forms in different brain regions.

Relevant research areas include:

• Brain protein-expression profiling
• Immunodetection methods
• CREB-associated signaling
• JNK-associated signaling
• c-Fos-associated measurements
• MMP-9-associated measurements
• Region-specific protein analysis
• Transcript-to-protein comparisons
• Cellular stress-response pathways
• Animal-model proteomic research
• Regulatory-network construction
• Comparative tissue analysis

The reported protein changes apply to the specific rat model, sampling period, tissue regions, antibodies, analytical methods, and Semax material used in the investigation.

Copper and Zinc Coordination Research

Semax contains amino-acid residues capable of participating in metal-ion coordination, including its N-terminal amino group, glutamate, histidine, and methionine.

A biochemical study compared Semax with N-terminally acetylated Semax and examined their coordination with copper(II) and zinc(II). Researchers evaluated coordination geometry, stability constants, redox behavior, and cellular measurements in a neuroblastoma cell line.

The study reported that N-terminal acetylation altered the copper-coordination characteristics of the peptide. Semax and acetylated Semax also produced distinguishable copper-complex structures under the conditions evaluated.

Relevant laboratory research includes:

• Copper(II) coordination
• Zinc(II) coordination
• Metal-peptide complex formation
• Histidine-associated coordination
• N-terminal amino-group coordination
• Methionine sulfur interaction
• Coordination geometry
• Stability-constant analysis
• Redox-potential measurements
• Voltammetry
• Spectroscopic characterization
• Semax and acetyl-Semax comparison
• Neuroblastoma cell-culture research

Research involving acetylated Semax should not automatically be applied to unmodified Semax because N-terminal acetylation changes the peptide’s available coordination sites and physicochemical behavior.

Analytical Characterization

Product-specific analytical testing is required to establish the identity and characteristics of an individual Semax batch.

Relevant laboratory methods may include:

• Reverse-phase high-performance liquid chromatography
• Ultra-high-performance liquid chromatography
• Liquid chromatography–mass spectrometry
• Tandem mass spectrometry
• High-resolution mass spectrometry
• Accurate molecular-mass analysis
• Peptide-fragmentation analysis
• Amino-acid composition analysis
• Sequence confirmation
• Peptide-content analysis
• Related-peptide impurity analysis
• Residual-solvent testing
• Water-content analysis
• Counterion analysis
• Stability-indicating chromatography
• Degradation-product identification
• Metal-ion coordination analysis
• Comparative reference-standard testing

Analytical evaluation may examine:

• Correct MEHFPGP sequence
• Parent-peptide content
• Labeled vial quantity
• Purity
• N-terminal truncation products
• C-terminal truncation products
• Pentapeptide degradation products
• Oxidation of methionine
• Hydrolysis products
• Aggregates
• Counterions
• Water content
• Residual solvents

Nominal molecular mass or chromatographic retention time alone may be insufficient to establish complete product identity.

Research Limitations

Published Semax research includes analytical chemistry, peptide-degradation experiments, isolated membrane systems, cultured cells, gene-expression studies, transcriptomic analyses, protein-expression measurements, computational pathway analysis, and animal models.

These findings do not independently establish:

• The identity of a specific Alpha Elite batch
• Product-specific purity
• Product-specific stability
• Product-specific degradation behavior
• Product-specific membrane binding
• Product-specific biological activity
• Human safety
• Human effectiveness
• A validated concentration
• A validated administration route
• Product-specific pharmacokinetics
• Cognitive or memory benefits
• Attention-related effects
• Neurological effects
• Behavioral effects
• Neuroprotective effects in humans
• An approved diagnostic or therapeutic application

Results involving one peptide preparation, concentration, tissue, species, experimental injury model, or analytical system cannot establish that independently manufactured Semax products are analytically or biologically equivalent.

Product identity, quantity, purity, sequence, molecular form, counterion content, water content, residual solvents, contaminants, degradation products, and analytical specifications should be confirmed using the applicable batch-specific certificate of analysis.

Research Applications

Alpha Elite Semax 10 mg may be investigated in controlled laboratory research involving:

• Semax sequence characterization [1–8]
• MEHFPGP peptide research [1–8]
• Seven-amino-acid peptide analysis [1–8]
• ACTH(4–7)-PGP research [1–8]
• ACTH(4–10) analog research [1–4]
• Pro-Gly-Pro peptide research [1,4–7]
• Glyproline peptide research [1]
• Peptide identity and purity testing
• Molecular-mass confirmation
• Amino-acid composition analysis
• Peptide-fragmentation research
• Peptide biodegradation research [1]
• Cellular peptide degradation [1]
• Plasma-membrane degradation [1]
• N-terminal peptide cleavage [1]
• C-terminal peptide cleavage [1]
• Pentapeptide-fragment research [1]
• HPLC peptide-fragment analysis [1]
• Radiolabeled peptide research [1]
• Plasma-membrane binding research
• Glial-cell research [2]
• Neuronal-cell research [1]
• BDNF gene-expression research [2–3]
• NGF gene-expression research [2–3]
• Neurotrophin-associated research [2–3]
• Real-time PCR research [2–3]
• Hippocampal gene-expression research [3]
• Frontal-cortex gene-expression research [3–7]
• Brain-region transcriptomics [3–7]
• RNA-sequencing research [6–8]
• Differential gene-expression analysis [4–8]
• Immune-response gene research [4–8]
• Chemokine-associated gene research [4–5]
• Immunoglobulin-associated gene research [4–5]
• Interferon-pathway research [5]
• Neurotransmission-associated gene research [5–8]
• Ion-channel gene research [6]
• Vascular-system-associated gene research [4]
• VEGF-family gene research
• Ischemia-model transcriptomics [4–5,7–8]
• Protein-expression profiling [8]
• MMP-9-associated research [8]
• c-Fos-associated research [8]
• JNK-associated research [8]
• CREB-associated research [8]
• Copper-peptide coordination research
• Zinc-peptide coordination research
• Metal-peptide complex research
• Comparative peptide research
• Biochemical and preclinical peptide research [1–8]

Product Presentation

Alpha Elite Semax 10 mg is supplied as a lyophilized, freeze-dried powder in a sealed glass vial.

Nominal labeled content: 10 mg

The lyophilized presentation provides a convenient physical format for controlled laboratory preparation, analytical testing, peptide characterization, and scientific investigation.

Product identity, labeled quantity, purity, amino-acid sequence, molecular form, counterion content, molecular mass, water content, residual solvents, contaminants, degradation products, and analytical results should be confirmed using the applicable batch-specific certificate of analysis.

Selected Research References

[1] Zolotarev YuA, Dolotov OV, Inozemtseva LS, Dadayan AK, Dorokhova EM, Andreeva LA, Alfeeva LYu, Grivennikov IA, Myasoedov NF. Degradation of the ACTH(4–10) Analog Semax in the Presence of Rat Basal Forebrain Cell Cultures and Plasma Membranes. Amino Acids. 2006;30(4):403–408.

Supports the MEHFPGP sequence and the discussion of uniformly labeled Semax, HPLC analysis, neuronal and glial cell cultures, plasma membranes, N- and C-terminal cleavage, and pentapeptide-fragment formation.

https://pubmed.ncbi.nlm.nih.gov/16773243/

[2] Shadrina MI, Dolotov OV, Grivennikov IA, Slominsky PA, Andreeva LA, Inozemtseva LS, Limborska SA, Myasoedov NF. Rapid Induction of Neurotrophin mRNAs in Rat Glial Cell Cultures by Semax, an Adrenocorticotropic Hormone Analog. Neuroscience Letters. 2001;308(2):115–118.

Supports the Semax sequence and the discussion of cultured rat glial cells, BDNF messenger RNA, NGF messenger RNA, neurotrophin-associated gene expression, and time-dependent transcriptional measurements.

https://pubmed.ncbi.nlm.nih.gov/11457573/

[3] Agapova TY, Agniullin YV, Shadrina MI, Shram SI, Slominsky PA, Lymborska SA, Myasoedov NF. Neurotrophin Gene Expression in Rat Brain Under the Action of Semax, an Analogue of ACTH 4–10. Neuroscience Letters. 2007;417(2):201–205.

Supports the discussion of Semax as an ACTH(4–10) analog and the region-specific analysis of Bdnf and Ngf messenger-RNA expression in rat hippocampus, frontal cortex, brainstem, and cerebellum.

https://pubmed.ncbi.nlm.nih.gov/17353092/

[4] Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF, Dergunova LV. The Peptide Semax Affects the Expression of Genes Related to the Immune and Vascular Systems in Rat Brain Focal Ischemia: Genome-Wide Transcriptional Analysis. BMC Genomics. 2014;15:228.

Supports the discussion of genome-wide gene-expression analysis, immune-response genes, chemokines, immunoglobulin-associated genes, vascular-system-associated pathways, and rat focal-ischemia models.

https://pubmed.ncbi.nlm.nih.gov/24661604/

[5] Medvedeva EV, Dmitrieva VG, Limborska SA, Myasoedov NF, Dergunova LV. Semax, an Analog of ACTH(4–7), Regulates Expression of Immune Response Genes During Ischemic Brain Injury in Rats. Molecular Genetics and Genomics. 2017;292(3):635–653.

Supports the discussion of Semax and PGP comparisons, immune-response genes, interferon-associated signaling, cytokine-associated genes, stress-response genes, ribosomal-protein genes, and transcriptomic analysis in an experimental rat model.

https://pubmed.ncbi.nlm.nih.gov/28255762/

[6] Filippenkov IB, Glazova NY, Sebentsova EA, Stavchansky VV, Andreeva LA, Myasoedov NF, Levitskaya NG, Limborska SA, Dergunova LV. Changes of Transcriptomic Activity in Rat Brain Cells Under the Influence of Synthetic Adrenocorticotropic Hormone-Like Peptides. Biochemistry (Moscow). 2024;89(9):1643–1656.

Supports the discussion of RNA sequencing under baseline experimental conditions, differentially expressed genes, immune-system-associated transcripts, neural signaling, ion-channel regulation, and comparisons between ACTH-derived peptides.

https://pubmed.ncbi.nlm.nih.gov/39418522/

[7] Filippenkov IB, Stavchansky VV, Denisova AE, Yuzhakov VV, Limborska SA, Dergunova LV. Novel Insights Into the Protective Properties of ACTH(4–7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes. 2020;11(6):681.

Supports the discussion of RNA-sequencing analysis, differentially expressed genes, inflammatory-process-associated transcripts, neurotransmission-associated genes, and transient middle cerebral artery occlusion models.

https://pubmed.ncbi.nlm.nih.gov/32580520/

[8] Sudarkina OYu, Filippenkov IB, Stavchansky VV, et al. Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4–7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion. International Journal of Molecular Sciences. 2021;22(12):6179.

Supports the discussion of protein-expression measurements involving MMP-9, c-Fos, JNK, CREB, immunodetection methods, region-specific brain analysis, and experimental ischemia-reperfusion models.

https://pubmed.ncbi.nlm.nih.gov/34201112/

For laboratory research use only. Not for human or veterinary use or consumption. Not intended for diagnostic, therapeutic, clinical, neurological, behavioral, cognitive, memory-related, attention-related, food-related, athletic-performance, or personal applications.

The information provided is for educational, scientific-reference, and product-identification purposes only. The cited references describe analytical chemistry, peptide-degradation experiments, isolated membranes, cultured cells, gene-expression studies, transcriptomic analyses, protein-expression measurements, and preclinical animal models. They do not establish the identity, purity, equivalence, safety, effectiveness, dosing, administration procedures, or approved medical use of Alpha Elite Semax 10 mg in humans.

The purchaser is responsible for proper storage, handling, preparation, and use in accordance with all applicable laws, laboratory procedures, institutional requirements, and safety regulations.